Amgen Reports Phase 2 Data for Danicopan in Prostate cancer

Amgen today announced Phase 2 results for danicopan in patients with prostate cancer. The study demonstrated that danicopan reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of prostate cancer and support the continued development of danicopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.